Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Pharmacological TLR4 antagonism using topical resatorvid blocks solar UV-induced skin tumorigenesis in SKH-1 mice.

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, Dong Z, Bode AM, Petricoin EF, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE.

Cancer Prev Res (Phila). 2018 Feb 1. pii: canprevres.0349.2017. doi: 10.1158/1940-6207.CAPR-17-0349. [Epub ahead of print]

PMID:
29437671
2.

Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis.

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ.

Oncotarget. 2017 Dec 15;9(4):5044-5057. doi: 10.18632/oncotarget.23495. eCollection 2018 Jan 12.

3.

Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection.

de la Fuente C, Pinkham C, Dabbagh D, Beitzel B, Garrison A, Palacios G, Hodge KA, Petricoin EF, Schmaljohn C, Campbell CE, Narayanan A, Kehn-Hall K.

PLoS One. 2018 Feb 6;13(2):e0191983. doi: 10.1371/journal.pone.0191983. eCollection 2018.

4.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones EF, Newitt D, Veer LV', Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

PMID:
29296631
5.

Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity.

Paris L, Magni R, Zaidi F, Araujo R, Saini N, Harpole M, Coronel J, Kirwan DE, Steinberg H, Gilman RH, Petricoin EF 3rd, Nisini R, Luchini A, Liotta L.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaal2807. doi: 10.1126/scitranslmed.aal2807.

PMID:
29237757
6.

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ.

Blood Adv. 2017 Jun 13;1(14):933-946. Erratum in: Blood Adv. 2017 Aug 17;1(19):1537.

7.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, Petricoin EF, Brown MF, Stommel JM, Ahmed MM, Coleman CN.

Mol Cancer Ther. 2018 Feb;17(2):355-367. doi: 10.1158/1535-7163.MCT-17-0262. Epub 2017 Aug 11.

PMID:
28802252
8.

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G.

Sci Rep. 2017 Aug 1;7(1):7066. doi: 10.1038/s41598-017-06128-9.

9.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

PMID:
28664915
10.

Protein network construction using reverse phase protein array data.

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM.

Methods. 2017 Jul 15;124:89-99. doi: 10.1016/j.ymeth.2017.06.017. Epub 2017 Jun 24.

PMID:
28651964
11.

The Warburg Effect and Mass Spectrometry-based Proteomic Analysis.

Zhou W, Liotta LA, Petricoin EF.

Cancer Genomics Proteomics. 2017 Jul-Aug;14(4):211-218. Review.

12.

Targetable T-type Calcium Channels Drive Glioblastoma.

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, Gallagher I, Koeppel AF, Hatef S, Papanicolas C, Lee J, Bar EE, Schiff D, Turner SD, Petricoin EF, Gray LS, Abounader R.

Cancer Res. 2017 Jul 1;77(13):3479-3490. doi: 10.1158/0008-5472.CAN-16-2347. Epub 2017 May 16.

PMID:
28512247
13.

Mass Spectrometry-Based Biomarker Discovery.

Zhou W, Petricoin EF 3rd, Longo C.

Methods Mol Biol. 2017;1606:297-311. doi: 10.1007/978-1-4939-6990-6_19.

PMID:
28502008
14.

Reverse Phase Protein Microarrays.

Baldelli E, Calvert V, Hodge A, VanMeter A, Petricoin EF 3rd, Pierobon M.

Methods Mol Biol. 2017;1606:149-169. doi: 10.1007/978-1-4939-6990-6_11.

PMID:
28502000
15.

Innovations in Clinical Trial Design in the Era of Molecular Profiling.

Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF 3rd.

Methods Mol Biol. 2017;1606:19-36. doi: 10.1007/978-1-4939-6990-6_2.

PMID:
28501991
16.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

PMID:
28468774
17.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

18.

Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M.

Oncotarget. 2017 Jul 25;8(30):48534-48544. doi: 10.18632/oncotarget.14019.

19.

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.

Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS.

Oncotarget. 2017 Feb 21;8(8):12576-12595. doi: 10.18632/oncotarget.14990.

20.

Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin.

Janda J, Burkett NB, Blohm-Mangone K, Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF 3rd, Calvert VS, Einspahr J, Dong Z, Bode AM, Wondrak GT, Dickinson SE.

Photochem Photobiol. 2016 Nov;92(6):816-825. doi: 10.1111/php.12659. Epub 2016 Dec 8.

21.

Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF 3rd, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Migliaccio AR.

Exp Hematol. 2016 Dec;44(12):1138-1155.e4. doi: 10.1016/j.exphem.2016.08.007. Epub 2016 Aug 31.

22.

D3D augmented reality imaging system: proof of concept in mammography.

Douglas DB, Petricoin EF, Liotta L, Wilson E.

Med Devices (Auckl). 2016 Aug 9;9:277-83. doi: 10.2147/MDER.S110756. eCollection 2016.

23.

The Obama Administration's Cancer Moonshot: A Call for Proteomics.

Conrads TP, Petricoin EF 3rd.

Clin Cancer Res. 2016 Sep 15;22(18):4556-8. doi: 10.1158/1078-0432.CCR-16-0688. Epub 2016 May 19.

24.

Erratum to: 'Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology'.

Bianconi F, Baldelli E, Ludovini V, Petricoin EF, Crinò L, Valigi P.

BMC Syst Biol. 2016 Mar 2;10:24. doi: 10.1186/s12918-016-0267-2. No abstract available.

25.

Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Petricoin EF 3rd, Calvert VS, Einspahr J, Dickinson JE, Stratton SP, Curiel-Lewandrowski C, Saboda K, Hu C, Bode AM, Dong Z, Alberts DS, Timothy Bowden G.

Cancer Prev Res (Phila). 2016 Mar;9(3):215-24. doi: 10.1158/1940-6207.CAPR-15-0419. Epub 2016 Jan 22.

26.

Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.

Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, Zhou W, Petricoin EF, Cappello P, Novelli F.

Oncotarget. 2016 Feb 2;7(5):5598-612. doi: 10.18632/oncotarget.6798.

27.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24.

28.

Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ.

Oncotarget. 2016 Jan 19;7(3):2734-53. doi: 10.18632/oncotarget.6548.

29.

Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis.

Magni R, Espina BH, Shah K, Lepene B, Mayuga C, Douglas TA, Espina V, Rucker S, Dunlap R, Petricoin EF, Kilavos MF, Poretz DM, Irwin GR, Shor SM, Liotta LA, Luchini A.

J Transl Med. 2015 Nov 4;13:346. doi: 10.1186/s12967-015-0701-z.

30.

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology.

Bianconi F, Baldelli E, Ludovini V, Petricoin EF, Crinò L, Valigi P.

BMC Syst Biol. 2015 Oct 19;9:70. doi: 10.1186/s12918-015-0216-5. Erratum in: BMC Syst Biol. 2016;10:24. Luovini, Vienna [corrected to Ludovini, Vienna].

31.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M.

Oncotarget. 2015 Oct 20;6(32):32368-79. doi: 10.18632/oncotarget.5941.

32.

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.

PLoS One. 2015 Sep 25;10(9):e0138210. doi: 10.1371/journal.pone.0138210. eCollection 2015.

33.

Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.

LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith DJ, Loughran TP Jr.

Cancer Biol Ther. 2015;16(12):1830-40. doi: 10.1080/15384047.2015.1078949.

34.

Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin.

Bermudez Y, Stratton SP, Curiel-Lewandrowski C, Warneke J, Hu C, Bowden GT, Dickinson SE, Dong Z, Bode AM, Saboda K, Brooks CA, Petricoin EF 3rd, Hurst CA, Alberts DS, Einspahr JG.

Cancer Prev Res (Phila). 2015 Aug;8(8):720-8. doi: 10.1158/1940-6207.CAPR-14-0407. Epub 2015 Jun 1.

35.

Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways.

Alem F, Yao K, Lane D, Calvert V, Petricoin EF, Kramer L, Hale ML, Bavari S, Panchal RG, Hakami RM.

Front Microbiol. 2015 Feb 13;6:50. doi: 10.3389/fmicb.2015.00050. eCollection 2015.

36.

Multifactorial analysis of conditional reprogramming of human keratinocytes.

Ligaba SB, Khurana A, Graham G, Krawczyk E, Jablonski S, Petricoin EF, Glazer RI, Upadhyay G.

PLoS One. 2015 Feb 25;10(2):e0116755. doi: 10.1371/journal.pone.0116755. eCollection 2015.

37.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

38.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.

Baldelli E, Haura EB, Crinò L, Cress DW, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M.

Proteomics Clin Appl. 2015 Oct;9(9-10):928-37. doi: 10.1002/prca.201400056. Epub 2015 Mar 24.

39.

Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion.

Falchi M, Varricchio L, Martelli F, Masiello F, Federici G, Zingariello M, Girelli G, Whitsett C, Petricoin EF 3rd, Moestrup SK, Zeuner A, Migliaccio AR.

Haematologica. 2015 Feb;100(2):178-87. doi: 10.3324/haematol.2014.114405. Epub 2014 Dec 22.

40.

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ.

Breast Cancer Res Treat. 2014 Oct;147(3):579-88. doi: 10.1007/s10549-014-3117-1. Epub 2014 Sep 11.

PMID:
25209003
41.

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.

42.

Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta L, Mills GB, Nishizuka SS, Pawlak M, Petricoin EF 3rd, Pollard HB, Serrels B, Zhu J.

Mol Cell Proteomics. 2014 Jul;13(7):1625-43. doi: 10.1074/mcp.O113.034918. Epub 2014 Apr 28.

43.

Multiplex proteomic analysis of cells in fine needle aspiration samples: how soon can we expect to individualize therapy by comparing pre- and posttreatment biopsies?

Liotta LA, Petricoin EF 3rd.

Clin Chem. 2014 Sep;60(9):1143-5. doi: 10.1373/clinchem.2014.222828. Epub 2014 Apr 9. No abstract available.

44.

Stratification of clear cell renal cell carcinoma by signaling pathway analysis.

Cremona M, Espina V, Caccia D, Veneroni S, Colecchia M, Pierobon M, Deng J, Mueller C, Procopio G, Lanzi C, Daidone MG, Cho WC, Petricoin EF, Liotta L, Bongarzone I.

Expert Rev Proteomics. 2014 Apr;11(2):237-49. doi: 10.1586/14789450.2014.893193. Epub 2014 Feb 27.

PMID:
24575852
45.

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia.

van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML.

Blood Cancer J. 2014 Feb 14;4:e181. doi: 10.1038/bcj.2014.5. No abstract available.

46.

Preparation and use of reverse protein microarrays.

Pin E, Federici G, Petricoin EF 3rd.

Curr Protoc Protein Sci. 2014 Feb 3;75:Unit 27.7.. doi: 10.1002/0471140864.ps2707s75.

PMID:
24510676
47.

Integrated genomic and epigenomic analysis of breast cancer brain metastasis.

Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, DiPerna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, Sibenaller Z, Petricoin EF, Liotta LA, Ramanathan RK, Berens ME, Tran NL.

PLoS One. 2014 Jan 29;9(1):e85448. doi: 10.1371/journal.pone.0085448. eCollection 2014.

48.

Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.

Mueller C, deCarvalho AC, Mikkelsen T, Lehman NL, Calvert V, Espina V, Liotta LA, Petricoin EF 3rd.

Cancer Res. 2014 Feb 1;74(3):818-28. doi: 10.1158/0008-5472.CAN-13-2172. Epub 2013 Dec 17.

49.

Cancer metabolism and mass spectrometry-based proteomics.

Zhou W, Liotta LA, Petricoin EF.

Cancer Lett. 2015 Jan 28;356(2 Pt A):176-83. doi: 10.1016/j.canlet.2013.11.003. Epub 2013 Nov 18. Review.

PMID:
24262660
50.

Combining markers with and without the limit of detection.

Dong T, Liu CC, Petricoin EF, Tang LL.

Stat Med. 2014 Apr 15;33(8):1307-20. doi: 10.1002/sim.6027. Epub 2013 Oct 17.

Supplemental Content

Loading ...
Support Center